表紙
市場調查報告書

猝睡症:開發中產品分析

Narcolepsy - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 227548
出版日期 內容資訊 英文 92 Pages
訂單完成後即時交付
價格
Back to Top
猝睡症:開發中產品分析 Narcolepsy - Pipeline Review, H2 2019
出版日期: 2019年12月02日內容資訊: 英文 92 Pages
簡介

所謂猝睡症是指過度嗜睡,一天頻繁嗜睡這樣的睡眠障礙。主要症狀有一天下來過度嗜睡(EDS)及四肢無力、幻覺、睡眠時麻痺(鬼壓床)等。主要治療方法有改善生活習慣及藥物療法、心理諮詢等。

本報告提供全球各國治療猝睡症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

猝睡症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

猝睡症:企業開發中的治療藥

猝睡症:大學/機關研究中的治療藥

猝睡症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

猝睡症:企業開發中的產品

猝睡症:大學/機關研究中的產品

猝睡症的治療藥開發企業

  • Bioprojet SCR
  • Evotec AG
  • Flamel Technologies S.A.
  • H.A.C. Pharma
  • Jazz Pharmaceuticals Plc
  • NLS Pharma Group
  • Sanofi
  • SK Biopharmaceuticals Co., Ltd.
  • Taisho Pharmaceutical Holdings Co., Ltd.
  • Theranexus SAS

猝睡症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

猝睡症:最近的開發平台趨勢

猝睡症:暫停中的計劃

猝睡症:開發中止的產品

猝睡症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11597IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2019, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.

Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 6, 2 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Narcolepsy - Overview
  • Narcolepsy - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Narcolepsy - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Narcolepsy - Companies Involved in Therapeutics Development
  • Avadel Pharmaceuticals Plc
  • Axsome Therapeutics Inc
  • Balance Therapeutics Inc
  • Bioprojet SCR
  • F. Hoffmann-La Roche Ltd
  • Jazz Pharmaceuticals Plc
  • NLS Pharma Group
  • Ono Pharmaceutical Co Ltd
  • Seelos Therapeutics, Inc.
  • SK Biopharmaceuticals Co Ltd
  • Suven Life Sciences Ltd
  • Takeda Pharmaceutical Co Ltd
  • Theranexus SAS
  • Vallon Pharmaceuticals Inc
  • XW Laboratories Inc
  • Narcolepsy - Drug Profiles
  • (flecainide acetate + modafinil) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • arbaclofen - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dextroamphetamine IR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JZP-258 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JZP-507 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • mazindol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NLS-4 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ONO-4127 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Oxybate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pentylenetetrazol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pitolisant hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • reboxetine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RO-5256390 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SLS-010 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sodium oxybate ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • solriamfetol hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SUVNG-3031 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TAK-925 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TAK-994 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XWL-008 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YNT-185 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Narcolepsy - Dormant Projects
  • Narcolepsy - Discontinued Products
  • Narcolepsy - Product Development Milestones
  • Featured News & Press Releases
  • Nov 25, 2019: Avadel Pharmaceuticals achieves enrollment target in REST-ON phase 3 pivotal trial of FT218 for excessive daytime sleepiness and Cataplexy in patients with Narcolepsy
  • Nov 20, 2019: Harmony Biosciences announces publication of data in sleep from two clinical studies of WAKIX (pitolisant)
  • Nov 18, 2019: Jazz Pharma's sleepiness drug solriamfetol gets CHMP recommendation
  • Oct 21, 2019: Axsome Therapeutics completes patient enrollment in the CONCERT Phase 2 trial of AXS-12 in narcolepsy
  • Oct 02, 2019: Axsome Therapeutics to Provide Update on AXS-12 at the 2019 Cantor Global Healthcare Conference
  • Sep 26, 2019: New data presented on TAK-994, an oral selective OX2R agonist at World Sleep Congress
  • Sep 26, 2019: New data presented at World Sleep Congress demonstrate early signs of efficacy for TAK-925,, a selective orexin type-2 receptor (OX2R) agonist, in patients with narcolepsy type 1
  • Sep 25, 2019: Jazz Pharmaceuticals presents positive JZP-258 phase 3 study data at World Sleep 2019
  • Sep 24, 2019: First patient randomized in a Phase 2A, Proof of Concept (PoC) clinical trial of SUVN-G3031 for the treatment of Narcolepsy associated with or without Cataplexy in USA
  • Sep 24, 2019: Avadel Pharmaceuticals announces pharmacokinetic (PK) data for once-nightly FT218 that will be included in an oral presentation at the World Sleep 2019 Congress on September 25th
  • Sep 23, 2019: Avadel Pharmaceuticals announces FDA agreement to reduce the sample size for the ongoing pivotal phase 3 study for once-nightly FT218; full enrollment now expected by end of 2019
  • Sep 18, 2019: Avadel Pharmaceuticals announces an oral presentation on investigational once-nightly Sodium Oxybate (FT218) at the World Sleep 2019 Congress on September 25th
  • Sep 16, 2019: Harmony Biosciences to present clinical data on WAKIX (pitolisant) at Upcoming World Sleep 2019
  • Aug 15, 2019: Harmony Biosciences announces FDA approval Of WAKIX (Pitolisant), a first-in-class medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy
  • Jun 24, 2019: FDA grants orphan drug designation to XW Laboratories XWL-008 for the treatment of patients with Narcolepsy
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Narcolepsy, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Narcolepsy - Pipeline by Avadel Pharmaceuticals Plc, H2 2019
  • Narcolepsy - Pipeline by Axsome Therapeutics Inc, H2 2019
  • Narcolepsy - Pipeline by Balance Therapeutics Inc, H2 2019
  • Narcolepsy - Pipeline by Bioprojet SCR, H2 2019
  • Narcolepsy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
  • Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H2 2019
  • Narcolepsy - Pipeline by NLS Pharma Group, H2 2019
  • Narcolepsy - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
  • Narcolepsy - Pipeline by Seelos Therapeutics, Inc., H2 2019
  • Narcolepsy - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2019
  • Narcolepsy - Pipeline by Suven Life Sciences Ltd, H2 2019
  • Narcolepsy - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
  • Narcolepsy - Pipeline by Theranexus SAS, H2 2019
  • Narcolepsy - Pipeline by Vallon Pharmaceuticals Inc, H2 2019
  • Narcolepsy - Pipeline by XW Laboratories Inc, H2 2019
  • Narcolepsy - Dormant Projects, H2 2019
  • Narcolepsy - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Narcolepsy - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Narcolepsy, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top